These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 36407843)

  • 1. ENhANCE trial protocol: A multi-centre, randomised, phase IV trial comparing the efficacy of oxycodone/naloxone prolonged release (OXN PR) versus oxycodone prolonged release (Oxy PR) tablets in patients with advanced cancer.
    Wong AK; Grobler A; Le B
    Contemp Clin Trials Commun; 2022 Dec; 30():101036. PubMed ID: 36407843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolonged-Release (PR) Oxycodone/Naloxone Improves Bowel Function Compared with Oxycodone PR and Provides Effective Analgesia in Chinese Patients with Non-malignant Pain: A Randomized, Double-Blind Trial.
    Leng X; Zhang F; Yao S; Weng X; Lu K; Chen G; Huang M; Huang Y; Zeng X; Hopp M; Lu G
    Adv Ther; 2020 Mar; 37(3):1188-1202. PubMed ID: 32020565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with prolonged-release oxycodone/naloxone improves pain relief and opioid-induced constipation compared with prolonged-release oxycodone in patients with chronic severe pain and laxative-refractory constipation.
    Poelaert J; Koopmans-Klein G; Dioh A; Louis F; Gorissen M; Logé D; Van Op den Bosch J; van Megen YJ
    Clin Ther; 2015 Apr; 37(4):784-92. PubMed ID: 25757607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fixed ratio (2:1) prolonged-release oxycodone/naloxone combination improves bowel function in patients with moderate-to-severe pain and opioid-induced constipation refractory to at least two classes of laxatives.
    Koopmans G; Simpson K; De Andrés J; Lux EA; Wagemans M; Van Megen Y
    Curr Med Res Opin; 2014 Nov; 30(11):2389-96. PubMed ID: 25265132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial.
    Löwenstein O; Leyendecker P; Hopp M; Schutter U; Rogers PD; Uhl R; Bond S; Kremers W; Nichols T; Krain B; Reimer K
    Expert Opin Pharmacother; 2009 Mar; 10(4):531-43. PubMed ID: 19243306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opioid-Induced Constipation Relief From Fixed-Ratio Combination Prolonged-Release Oxycodone/Naloxone Compared With Oxycodone and Morphine for Chronic Nonmalignant Pain: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Huang L; Zhou JG; Zhang Y; Wang F; Wang Y; Liu DH; Li XJ; Lv SP; Jin SH; Bai YJ; Ma H
    J Pain Symptom Manage; 2017 Nov; 54(5):737-748.e3. PubMed ID: 28736104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term evaluation of combined prolonged-release oxycodone and naloxone in patients with moderate-to-severe chronic pain: pooled analysis of extension phases of two Phase III trials.
    Blagden M; Hafer J; Duerr H; Hopp M; Bosse B
    Neurogastroenterol Motil; 2014 Dec; 26(12):1792-801. PubMed ID: 25346155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolonged release oxycodone and naloxone treatment counteracts opioid-induced constipation in patients with severe pain compared to previous analgesic treatment.
    Koopmans-Klein G; Van Op den Bosch J; van Megen Y; Prenen H; Huygen F; Mancini I
    Curr Med Res Opin; 2017 Dec; 33(12):2217-2227. PubMed ID: 28805471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain.
    Ahmedzai SH; Nauck F; Bar-Sela G; Bosse B; Leyendecker P; Hopp M
    Palliat Med; 2012 Jan; 26(1):50-60. PubMed ID: 21937568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of prolonged-release oxycodone/naloxone on pain control, bowel function and quality of life: A prospective observational study.
    Hesselbarth S; Löwenstein O; Cegla T
    Scand J Pain; 2014 Apr; 5(2):75-81. PubMed ID: 29913668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term efficacy and safety of oxycodone-naloxone prolonged-release formulation (up to 180/90 mg daily) - results of the open-label extension phase of a phase III multicenter, multiple-dose, randomized, controlled study.
    Dupoiron D; Stachowiak A; Loewenstein O; Ellery A; Kremers W; Bosse B; Hopp M
    Eur J Pain; 2017 Oct; 21(9):1485-1494. PubMed ID: 28474460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of oxycodone/naloxone vs. oxycodone vs. morphine for the treatment of chronic low back pain: results of a 12 week prospective, randomized, open-label blinded endpoint streamlined study with prolonged-release preparations.
    Ueberall MA; Mueller-Schwefe GH
    Curr Med Res Opin; 2015; 31(7):1413-29. PubMed ID: 25942606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality of life benefits and cost impact of prolonged release oxycodone/naloxone versus prolonged release oxycodone in patients with moderate-to-severe non-malignant pain and opioid-induced constipation: a UK cost-utility analysis.
    Dunlop W; Uhl R; Khan I; Taylor A; Barton G
    J Med Econ; 2012; 15(3):564-75. PubMed ID: 22313329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of oral oxycodone and oxycodone/naloxone combination in opioid-naïve cancer patients: a propensity analysis.
    Lazzari M; Greco MT; Marcassa C; Finocchi S; Caldarulo C; Corli O
    Drug Des Devel Ther; 2015; 9():5863-72. PubMed ID: 26586937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of opioid-induced constipation: post hoc analysis of data from a 12-week prospective, open-label, blinded-endpoint streamlined study in low-back pain patients treated with prolonged-release WHO step III opioids.
    Ueberall MA; Mueller-Schwefe GH
    J Pain Res; 2015; 8():459-75. PubMed ID: 26300655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase III randomized controlled study on the efficacy and improved bowel function of prolonged-release (PR) oxycodone-naloxone (up to 160/80 mg daily) vs oxycodone PR.
    Dupoiron D; Stachowiak A; Loewenstein O; Ellery A; Kremers W; Bosse B; Hopp M
    Eur J Pain; 2017 Oct; 21(9):1528-1537. PubMed ID: 28641363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral Prolonged-Release Oxycodone/Naloxone for Managing Pain and Opioid-Induced Constipation: A Review of the Evidence.
    Morlion BJ; Mueller-Lissner SA; Vellucci R; Leppert W; Coffin BC; Dickerson SL; O'Brien T
    Pain Pract; 2018 Jun; 18(5):647-665. PubMed ID: 28944983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of controlled-release oxycodone/naloxone versus controlled-release oxycodone in Korean patients with cancer-related pain: a randomized controlled trial.
    Lee KH; Kim TW; Kang JH; Kim JS; Ahn JS; Kim SY; Yun HJ; Eum YJ; Koh SA; Kim MK; Hong YS; Kim JE; Lee GW
    Chin J Cancer; 2017 Sep; 36(1):74. PubMed ID: 28893309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High dosage of a fixed combination oxycodone/naloxone prolonged release: efficacy and tolerability in patients with chronic cancer pain.
    Amato F; Ceniti S; Mameli S; Pisanu GM; Vellucci R; Palmieri V; Consoletti L; Magaldi D; Notaro P; Marcassa C
    Support Care Cancer; 2017 Oct; 25(10):3051-3058. PubMed ID: 28470370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate-to-severe chronic cancer pain.
    Ahmedzai SH; Leppert W; Janecki M; Pakosz A; Lomax M; Duerr H; Hopp M
    Support Care Cancer; 2015 Mar; 23(3):823-30. PubMed ID: 25218610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.